Citalopram Versus Citalopram Plus Pindolol in Major Depressive Disorder (CIT-PIN)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Status and phase: Completed; Phase 2

Conditions: Major Depressive Disorder; Antidepressant Treatment Response

Treatments: Drug: Pindolol

Study type: Interventional

Funder types: Other

Identifiers

NCT00931775

CIT-PIN_01-0C3

Details and patient eligibility

About

The purpose of this study is to examine whether the speed of the clinical antidepressant action of citalopram can be accelerated by administering double doses of pindolol (15 mg/day, tid) which presumably should lead to increased 5-HT1A autoreceptor occupancy.

Full description

Design, Settings, and Participants. A randomised, double-blind, placebo-controlled trial with MDD patients allocated to two treatment arms: citalopram + pindolol versus citalopram + placebo. Participants: outpatients with a depressive episode (DSM-IV criteria) were selected from a general hospital.

Enrollment: 30 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with a depressive episode
• HDRS score > 18
• Written informed consent

Exclusion criteria

• suicidal risk > 3
• severe organic illness
• other psychotropic drugs

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

30 participants in 2 patient groups, including a placebo group

Citalopram + placebo

Placebo Comparator group

Description:

Citalopram 20 mg/day t.i.d

Treatment:

Drug: Pindolol

Citalopram + pindolol

Experimental group

Description:

Citalopram 20 mg/day t.i.d Pindolol 15 mg/day t.i.d.

Treatment:

Drug: Pindolol